Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer the NEfERT-T randomized clinical trial

JAMA Oncology

Volumn 2, Issue 12, 2016, Pages 1557-1564

  Awada, Ahmad ^a   Colomer, Ramon ^b   Inoue, Kenichi ^c   Bondarenko, Igor ^d   Badwe, Rajendra A ^e   Demetriou, Georgia ^f   Lee, Soo Chin ^g   Mehta, Ajay O ^h   Kim, Sung Bae ⁱ   Bachelot, Thomas ^j   Goswami, Chanchal ^k   Deo, Suryanarayan ^l   Bose, Ron ^m   Wong, Alvin ⁿ   Xu, Feng ⁿ   Yao, Bin ⁿ   Bryce, Richard ⁿ   Carey, Lisa A ^o  

^a JULES BORDET INSTITUTE   (Belgium)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c SAITAMA CANCER CENTER   (Japan)

^d Dnipropetrovsk State Medical Academy   (Ukraine)

^e TATA MEMORIAL HOSPITAL   (India)

^f University of the Witwatersrand   (South Africa)

^g Singapore Cancer Institute   (Singapore)

^h Central India Research Institute   (India)

ⁱ University of Ulsan   (South Korea)

^j CENTRE LÉON BÉRARD   (France)

^k B P Poddar Hospital and Medical Research Ltd   (India)

^l INSTITUTE ROTARY CANCER HOSPITAL   (India)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Puma Biotechnology Inc   (United States)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PACLITAXEL; QUINOLINE DERIVATIVE; TRASTUZUMAB;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PACLITAXEL; QUINOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 85013219022     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0237     Document Type: Article

References (38)

1. Slamon D, EiermannW, Robert N, et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
2. Goldhirsch A, Gelber RD, Piccart-GebhartMJ, et al.; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382 (9897):1021-1028.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11): 783-792.
4. Swain SM, Baselga J, Kim SB, et al.; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positivemetastatic breast cancer. N Engl J Med. 2015;372(8):724-734.
5. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressingmetastatic breast cancer. J Clin Oncol. 2013;31(16):1947-1953.
6. Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positivemetastatic breast cancer. Ann Oncol. 2014;25(3):592-598.
7. Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positivemetastatic breast cancer in the post-trastuzumab era. Breast. 2013;22 (4):525-531.
8. Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3): 244-248.
9. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positivemetastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71.
10. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.
11. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046-1051.
12. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958-3965.
13. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301-1307.
14. Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positivemetastatic breast cancer. Br J Cancer. 2013;108(10):1985-1993.
15. Besse B, Soria J, Yao B, et al. Neratinib with or without temsirolimus in patients with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study. Ann Oncol. 2014;25:1-41 (suppl 5; abstract LBA39-PR).
16. Gajria D, Modi S, Saura C, et al. A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy. http: //cancerres.aacrjournals.org/content/75/9-Supplement/P5-19-04.short?rss=1. Accessed March 13, 2015.
17. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(6): 976-983.
18. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy ofmetastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264-271.
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140-1154.
20. Eton DT, Cella D, Yost KJ, et al. A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898-910.
21. Pickard AS, NearyMP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
22. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line tk;3chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29(2):149-156.
23. Baselga J, Cortés J, Kim SB, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel formetastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
24. Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31(14):1719-1725.
25. Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat. 2010;119(1):127-136.
26. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressingmetastatic breast cancer. J Clin Oncol. 2006;24(18):2786-2792.
27. Pivot X, Manikhas A, Zurawski B, et al. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer. J Clin Oncol. 2015;33(14):1564-1573.
28. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113-119.
29. Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positivemetastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-1121.
30. Cameron D, CaseyM, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543.
31. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695-701.
32. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth ofmetastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008; 100(15):1092-1103.
33. Emanuel SL, Hughes TV, Adams M, et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol. 2008; 73(2):338-348.
34. Verma S, Miles D, Gianni L, et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367 (19):1783-1791.
35. Ellis AE, Barrios CH, EiermannW, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol. 2015;33:(suppl; abstract 507).
36. de Azambuja E, Holmes AP, Piccart-GebhartM, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137-1146.
37. Untch M, Loibl S, Bischoff J, et al.; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-144.
38. Piccart-GebhartMJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol. 2014;32:5.